Robert E. Landry
2016
In 2016, Robert E. Landry earned a total compensation of $5.2M as Senior Vice President, Finance and Chief Financial Officer at Regeneron Pharmaceuticals, a 37% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $439,200 |
|---|---|
| Option Awards | $4,121,229 |
| Salary | $585,600 |
| Other | $18,700 |
| Total | $5,164,729 |
Landry received $4.1M in option awards, accounting for 80% of the total pay in 2016.
Landry also received $439.2K in non-equity incentive plan, $585.6K in salary and $18.7K in other compensation.
Rankings
In 2016, Robert E. Landry's compensation ranked 1,537th out of 14,075 executives tracked by ExecPay. In other words, Landry earned more than 89.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,537 out of 14,075 | 89th |
Division Manufacturing | 527 out of 5,489 | 90th |
Major group Chemicals And Allied Products | 148 out of 1,895 | 92nd |
Industry group Drugs | 101 out of 1,538 | 93rd |
Industry Pharmaceutical Preparations | 81 out of 1,176 | 93rd |
Source: SEC filing on April 26, 2019.
Landry's colleagues
We found two more compensation records of executives who worked with Robert E. Landry at Regeneron Pharmaceuticals in 2016.
News
Regeneron Pharmaceuticals Executive Vice President and General Manager, Industrial Operations and Product Supply Daniel Van Plew's 2021 pay rises 1% to $8.8M
April 21, 2022
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2020 pay jumps 531% to $135M
April 23, 2021
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2019 pay slips 19% to $21M
April 24, 2020
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2018 pay stays at $27M
April 26, 2019